the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
Company profile
Ticker
VERU
Exchange
Website
CEO
Mitchell Steiner
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
FEMALE HEALTH CO
SEC CIK
Corporate docs
Subsidiaries
Aspen Park Pharmaceuticals, Inc. • Badger Acquisition Sub, Inc. • The Female Health Company Limited • The Female Health Company (UK) Plc. • The Female Health Company • Veru International Holdco Inc. • Veru Biopharma UK Limited • Veru Biopharma Europe Limited • Veru Biopharma Netherlands B.V. ...
IRS number
391144397
VERU stock data
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
22 May 24
DEFA14A
Additional proxy soliciting materials
9 May 24
DEFR14A
Revised proxy
9 May 24
10-Q
2024 Q2
Quarterly report
8 May 24
8-K
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
8 May 24
8-K
Entry into a Material Definitive Agreement
26 Apr 24
8-K
Other Events
25 Apr 24
DEFA14A
Additional proxy soliciting materials
1 Apr 24
10-Q
2024 Q1
Quarterly report
1 Apr 24
Transcripts
VERU
Earnings call transcript
2024 Q2
8 May 24
VERU
Earnings call transcript
2024 Q1
8 Feb 24
VERU
Earnings call transcript
2023 Q3
10 Aug 23
VERU
Earnings call transcript
2023 Q2
9 Aug 23
VERU
Earnings call transcript
2023 Q1
11 May 23
VERU
Earnings call transcript
2023 Q1
9 Feb 23
VERU
Earnings call transcript
2022 Q4
5 Dec 22
VERU
Earnings call transcript
2022 Q3
11 Aug 22
VERU
Earnings call transcript
2022 Q2
12 May 22
VERU
Earnings call transcript
2022 Q1
9 Feb 22
Latest ownership filings
4
HARRY FISCH
28 May 24
4
K GARY BARNETTE
24 May 24
4
MITCHELL SHUSTER STEINER
24 May 24
4
HARRY FISCH
17 May 24
4
MITCHELL SHUSTER STEINER
17 May 24
4
Michele Greco
9 May 24
4
K GARY BARNETTE
9 May 24
4
HARRY FISCH
9 May 24
4
MITCHELL SHUSTER STEINER
9 May 24
SC 13G
MILLENNIUM MANAGEMENT LLC
24 Apr 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
15.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 5 |
Closed positions | 56 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 128.13 mm |
Total shares | 22.75 mm |
Total puts | 400.00 |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
Adage Capital Partners GP, L.L.C. | 13.72 mm | $10.33 mm |
Phillip MD Frost Et Al | 5.10 mm | $4.22 mm |
MS Morgan Stanley | 3.76 mm | $3.59 mm |
Segment Wealth Management | 60.00 k | $43.20 mm |
Mendel Capital Management | 59.83 k | $43.08 mm |
Kingswood Wealth Advisors | 24.00 k | $17.28 mm |
SG Americas Securities | 16.63 k | $12.00 k |
Sound Income Strategies | 3.68 k | $2.65 mm |
Quent Capital | 2.44 k | $1.76 mm |
Cutler | 1.80 k | $1.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 May 24 | K Gary Barnette | Common Stock | Buy | Acquire P | No | No | 1.3393 | 5,000 | 6.70 k | 5,000 |
24 May 24 | Fisch Harry | Common Stock | Buy | Acquire P | No | No | 1.25 | 4,000 | 5.00 k | 774,736 |
24 May 24 | Steiner Mitchell Shuster | Common Stock | Sell | Dispose S | No | No | 1.2323 | 63,379 | 78.10 k | 6,942,709 |
23 May 24 | Steiner Mitchell Shuster | Common Stock | Sell | Dispose S | No | No | 1.35 | 300 | 405.00 | 7,006,088 |
22 May 24 | Steiner Mitchell Shuster | Common Stock | Sell | Dispose S | No | No | 1.3866 | 6,504 | 9.02 k | 7,006,388 |
17 May 24 | Steiner Mitchell Shuster | Common Stock | Sell | Dispose S | No | No | 1.3179 | 28,066 | 36.99 k | 7,012,892 |
16 May 24 | Steiner Mitchell Shuster | Common Stock | Sell | Dispose S | No | No | 1.4071 | 59,788 | 84.13 k | 7,040,958 |
15 May 24 | Steiner Mitchell Shuster | Common Stock | Sell | Dispose S | No | No | 1.4974 | 84,021 | 125.81 k | 7,100,746 |
15 May 24 | Fisch Harry | Common Stock | Buy | Acquire P | No | No | 1.49 | 6,711 | 10.00 k | 770,736 |
News
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
29 May 24
Comstock And 2 Other Stocks Under $2 Insiders Are Buying
29 May 24
B. Riley Securities Initiates Coverage On Veru with Buy Rating, Announces Price Target of $5
14 May 24
HC Wainwright & Co. Reiterates Buy on Veru, Maintains $3 Price Target
13 May 24
Veru Q2 2024 Adj EPS $(0.07) Misses $(0.05) Estimate, Sales $4.10M Beat $3.00M Estimate
8 May 24
Press releases
Veru to Present at the Jefferies Global Healthcare Conference
22 May 24
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
8 May 24
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
1 May 24
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
30 Apr 24
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
25 Apr 24